ORIGINAL RESEARCH article
Front. Gastroenterol.
Sec. Therapy in Gastroenterology
Volume 4 - 2025 | doi: 10.3389/fgstr.2025.1602541
This article is part of the Research TopicAdvances in Inflammatory Bowel Disease: Treatment, Targets and TherapyView all 5 articles
Curcumin-QingDai combination for patients with active Crohn's disease: A retrospective real-world multi-center cohort study
Provisionally accepted
Nir Salomon1
Maayan Marom2Safwat Odeh2Madlen Molnar2Ariella Bar-Gil Shitrit3Omri Nayshool1,4Bella Ungar1,4
Shomron Ben-Horin1,4*Tova Rainis2- 1Sheba Medical Center, Ramat Gan, Israel
- 2Bnai Zion Medical Center, The Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Haifa, Israel
- 3Shaare Zedek Medical Center, Jerusalem, Jerusalem, Israel
- 4Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Tel Aviv, Israel
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Takeda, Janssen, Celltrion, Pfizer, & Galmed. The Sheba Medical Center has filed intellectual property on the combination of curcumin and QD. EviNature is a spin-off company of Sheba center, Shomron Ben-Horin & Nir Salomon receive consulting fees and hold equity in EviNature. Bella Ungar received consultation fees from Neopharm, Takeda, Janssen and Abbvie and received research support from Abbvie. Ariealla Bar-Gil Shitrit received consulting/advisory fees from Takeda, Janssen, Neopharm Pfizer and AbbVie; Speaking and teaching fees from Takeda, Janssen, AbbVie, Neopharm , Lilly and Pfizer; and research support from Takeda and Janssen. The remaining authors declare that they have no conflicts of interest.
Keywords: Crohn Disease, Treatment, inflammatory bowel disease IBD -Inflammatory bowel disease, UC -ulcerative colitis, CD -Crohn's Disease, QD -QingDai, CurQD -Curcumin-QingDai combination, FCP -fecal calprotectin
Received: 29 Mar 2025; Accepted: 17 Jun 2025.
Copyright: © 2025 Salomon, Marom, Odeh, Molnar, Bar-Gil Shitrit, Nayshool, Ungar, Ben-Horin and Rainis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shomron Ben-Horin, Sheba Medical Center, Ramat Gan, Israel
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.